In this slideshow, we preview biosimilar studies due to be presented at the American College of Rheumatology annual meeting Nov. 11-16 in Washington, D.C.
Photo Clinic: A case of pyoderma gangrenosum that failed antibiotics, steroids, other immunosuppressive agents, thalidomide and cyclosporine.
In this slideshow, we highlight some of the upcoming studies due to be presented at the American College of Rheumatology 2016 annual meeting which begins Nov. 11 in Washington, D.C.
How do rheumatologists and primary care physicians differ in treating patients with gout? This survey highlights some notable differences.
Identifying the difference between Lyme arthritis or another inflammatory arthritis can be tricky. Here are key signs that your patient may have a systemic inflammatory arthritis rather than Lyme arthritis.
In this slideshow, we summarize the difference between primary and secondary Raynaud’s phenomenon and recommended treatments.
Low bone mineral density and osteoporosis are well-known comorbidities with systemic lupus erythematosus. In this slideshow, we highlight six of the most common risk factors for low bone mineral density in SLE.
For high risk patients with systemic lupus erythematosus, teriparatide and denosumab may be an option for patients who have failed bisphosphonates. Here are some key points you need to know.
In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.
Bisphosphonates, bone health and more: In this slideshow, we revisit some of the studies presented at the American Society for Bone and Mineral Research annual meeting, which took place Sept. 16-19 in Atlanta.